Related Experiment Video
Updated: Mar 15, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.8K
Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer
Pedro Cruz1, Cristina Boixareu1, Diogo J Silva1
1Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London SM2 5GP, UK.
Cancers
|March 14, 2026
Summary
Recent advances in non-oncogene-addicted non-small cell lung cancer therapy include new drugs and targets. Despite progress, challenges persist in late-stage trials, prompting innovative drug development strategies.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Non-oncogene-addicted non-small cell lung cancer (NSCLC) therapy has advanced significantly.
- New molecular targets and biomarkers have led to diverse drug classes like immunotherapies and antibody-drug conjugates.
- Phase I trials now focus on early efficacy signals alongside toxicity.
Purpose of the Study:
- To review the current state of drug development in non-oncogene-addicted NSCLC.
- To highlight recent advances, novel drugs, and emerging targets.
- To discuss challenges and opportunities in NSCLC drug development.
Main Methods:
- Review of current literature on NSCLC drug development.
- Analysis of advances in molecular targeting and biomarker discovery.
- Examination of challenges in late-stage clinical trial progression.
Main Results:
- Significant progress in developing targeted therapies and immunotherapies for NSCLC.
- Identification of new molecular targets and biomarkers.
- Persistent challenges in phase III trials, particularly in later lines of therapy.
Conclusions:
- Innovative biological rationales are driving the development of promising new drugs for NSCLC.
- Addressing late-stage trial failures is crucial for advancing NSCLC treatment.
- Continued research into novel targets and strategies is essential for improving patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:28Preclinical Development: Overview
6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K